Title:
COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
Document Type and Number:
WIPO Patent Application WO/2017/170348
Kind Code:
A1
Abstract:
Provided are methods, uses, and compositions for treating acute myeloid leukemia which includes therapeutically effective combinations of 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide, or a salt thereof, and 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, or a salt thereof.
Inventors:
ERKUT BAHCECI (US)
YAMAKI YOKO (JP)
YAMAKI YOKO (JP)
Application Number:
PCT/JP2017/012293
Publication Date:
October 05, 2017
Filing Date:
March 27, 2017
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
A61K31/497; A61K31/706; A61P35/00; A61P35/02; C07D405/14; C07H19/12
Other References:
DAVER, NAVAL ET AL.: "Acute myeloid leukemia: advancing clinical trials and promising therapeutics", EXPERT REVIEW OF HEMATOLOGY, vol. 9, 17 March 2016 (2016-03-17), pages 433 - 445, XP055578864, Retrieved from the Internet [retrieved on 20170525]
CHANG, E ET AL.: "The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells", LEUKEMIA, vol. 30, 15 January 2016 (2016-01-15), pages 1025 - 1032, XP055428704, [retrieved on 20170525]
UENO YOKO ET AL.: "2830 Gilteritinib(ASP2215), a Novel FTLT3/AXL Inhibitor:Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia", AMERICAN SOCIETY OF HEMATOLOGY 58TH ANNUAL MEETING & EXPOSION, 4 December 2016 (2016-12-04), XP055428707, Retrieved from the Internet [retrieved on 20170516]
See also references of EP 3436014A4
CHANG, E ET AL.: "The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells", LEUKEMIA, vol. 30, 15 January 2016 (2016-01-15), pages 1025 - 1032, XP055428704, [retrieved on 20170525]
UENO YOKO ET AL.: "2830 Gilteritinib(ASP2215), a Novel FTLT3/AXL Inhibitor:Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia", AMERICAN SOCIETY OF HEMATOLOGY 58TH ANNUAL MEETING & EXPOSION, 4 December 2016 (2016-12-04), XP055428707, Retrieved from the Internet
See also references of EP 3436014A4
Attorney, Agent or Firm:
MORIHIRA Koichiro et al. (JP)
Download PDF:
Previous Patent: METHOD FOR SEPARATING Dy AND Tb FROM ALLOY CONTAINING BOTH
Next Patent: TOILET DEVICE
Next Patent: TOILET DEVICE